CR20200415A - Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro - Google Patents

Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro

Info

Publication number
CR20200415A
CR20200415A CR20200415A CR20200415A CR20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A
Authority
CR
Costa Rica
Prior art keywords
bupropion
dosage forms
enantiomerically enriched
methods
pure bupropion
Prior art date
Application number
CR20200415A
Other languages
English (en)
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CR20200415A publication Critical patent/CR20200415A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20200415A 2018-02-23 2019-02-25 Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro CR20200415A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
CR20200415A true CR20200415A (es) 2021-02-03

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200415A CR20200415A (es) 2018-02-23 2019-02-25 Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro

Country Status (19)

Country Link
EP (1) EP3755312A4 (enrdf_load_stackoverflow)
JP (3) JP2021513998A (enrdf_load_stackoverflow)
KR (3) KR20230075531A (enrdf_load_stackoverflow)
CN (1) CN112087999A (enrdf_load_stackoverflow)
AU (3) AU2019223187B2 (enrdf_load_stackoverflow)
BR (1) BR112020017179A2 (enrdf_load_stackoverflow)
CA (1) CA3092076A1 (enrdf_load_stackoverflow)
CL (1) CL2020002166A1 (enrdf_load_stackoverflow)
CR (1) CR20200415A (enrdf_load_stackoverflow)
EC (1) ECSP20060179A (enrdf_load_stackoverflow)
IL (2) IL313368A (enrdf_load_stackoverflow)
MA (1) MA51914A (enrdf_load_stackoverflow)
MX (2) MX2020008704A (enrdf_load_stackoverflow)
MY (1) MY202993A (enrdf_load_stackoverflow)
NI (1) NI202000056A (enrdf_load_stackoverflow)
NZ (1) NZ767378A (enrdf_load_stackoverflow)
PE (1) PE20211752A1 (enrdf_load_stackoverflow)
SG (1) SG11202008056SA (enrdf_load_stackoverflow)
WO (1) WO2019165379A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2021055124A1 (en) * 2019-09-20 2021-03-25 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318960A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE60330909D1 (de) * 2003-08-08 2010-02-25 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
CA3092076A1 (en) 2019-08-29
KR20240091043A (ko) 2024-06-21
IL276871A (en) 2020-10-29
EP3755312A1 (en) 2020-12-30
BR112020017179A2 (pt) 2020-12-22
ECSP20060179A (es) 2020-12-31
NZ767378A (en) 2024-03-22
MX2023009281A (es) 2023-08-17
MY202993A (en) 2024-05-31
JP2024075655A (ja) 2024-06-04
AU2022204521A1 (en) 2022-07-21
CL2020002166A1 (es) 2020-10-23
MA51914A (fr) 2020-12-30
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
KR20230075531A (ko) 2023-05-31
JP2021513998A (ja) 2021-06-03
AU2019223187A1 (en) 2020-09-17
WO2019165379A1 (en) 2019-08-29
AU2022204521B2 (en) 2024-09-05
AU2024205858A1 (en) 2024-09-05
IL313368A (en) 2024-08-01
EP3755312A4 (en) 2022-03-16
JP2022153638A (ja) 2022-10-12
MX2020008704A (es) 2020-12-07
CN112087999A (zh) 2020-12-15
KR20210003091A (ko) 2021-01-11
AU2019223187B2 (en) 2022-07-28
NI202000056A (es) 2021-01-11
PE20211752A1 (es) 2021-09-06
IL276871B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
CR20200415A (es) Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
MX367209B (es) Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
DK1883387T3 (da) Beholder til flydende medikamenter, der skal administreres
BR112015001640A2 (pt) formulações e métodos de produção de formulações para uso em evacuação colônica
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
MX359672B (es) Metodo para manejo de dolor cronico y tratamiento usando hcg.
PH12022550738A1 (en) Dosages and uses of ornithine phenylacetate for treating hyperammonemia
MX381450B (es) Un medicamento combinado que comprende fenilefrina y paracetamol
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
PH12022550378A1 (en) Soft capsule containing tyndalized bacteria in film
UA120529U (uk) Спосіб збереження функції нирок у хворих, що страждають на подагру і метаболічний синдром
Angurana Low-Dose Epinephrine Boluses for Acute Hypotension in the PICU: Are They Needed?
Alyahya International normalised ratio elevation: case report
CR20220119A (es) Formas de dosificación para bupropión enantioméricamente enriquecido o puro
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
Hyun A Study on the Negative Common Idiomatic Phrase with Four Syllables in Modern Chinese
deFranco Legal Frameworks to Promote Inclusive Education for Children with Disabilities
Eliseeva Graphic Trends in New Russian Cinema
UA93429U (uk) Спосіб підвищення ефективності профілактики судинних ускладнень у хворих на остеоартроз
Vourvahis Lersivirine/methadone
UA127468U (uk) Спосіб підвищення життєздатності новонароджених ягнят з використанням препарату "карафест+оv"
AR091633A1 (es) Solucion inyectable de acetaminofen para su administracion por via espinal
Hanna Afective disorders: 9 case reports